Cipla’s shares surged 2% after Kotak upgraded the stock to “Buy” from “Add,” with a target price of Rs 1,725, slightly down from the previous Rs 1,750.
Despite the anticipated delay in the launch of gAbraxane until mid-FY2026, Kotak remains optimistic about its potential, highlighting it as an attractive opportunity for Cipla.
The firm also pointed to several promising launches in the US over the next 2.5 years and expects a steady recovery in the domestic market with an improved chronic mix and higher productivity. Kotak lowered Cipla’s FY2025-27E EPS by 1-3% to account for the delay, but believes most concerns are priced in at a 24X ex-gRevlimid FY27 PE.
Cipla shares opened at ₹1,470.00, reaching a high of ₹1,483.00 and a low of ₹1,462.75 today. The stock’s 52-week high stands at ₹1,702.05, while the 52-week low is ₹1,192.10.
As of 9:40 am, Cipla shares were trading 1.54% higher at Rs 1,470.80 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
